5 documents

Read All
08:00 , Dec 6, 2012 |  BC Innovations  |  Cover Story

A current affair in MS

A European team has used the diabetes drug glibenclamide to block inflammation-induced neurodegeneration in mice.1 The team plans to test the nonspecific inhibitor of the cationic channel TRPM4 in an investigator-led clinical trial in multiple...
Read More
07:00 , Oct 18, 2012 |  BC Innovations  |  Targets & Mechanisms

Black mamba takes away pain

A French team has identified a pair of peptides, mambalgin-1 and mambalgin-2, from black mamba venom that could be useful for treating pain.1 The peptides, which inhibit a class of acid-sensing ion channels on the...
Read More
07:00 , Oct 18, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Acid-sensing ion channel-1 (ASIC1); ASIC2 Cell culture and mouse studies suggest snake venom-derived peptides that antagonize...
Read More
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology ...
Read More
07:00 , Mar 13, 2008 |  BC Innovations  |  Targets & Mechanisms

Secretoneurin: twice is not enough

The graveyard of stroke compounds has been filled by both thrombolytics, which restore blood flow, and neuroprotectants, which protect brain tissue from infarction. Recently, researchers reported in The Journal of Clinical Investigation that the endogenous...
Read More